BRPI0814571A2 - Compostos moduladores de fxr, seu uso e composição compreendendo os mesmos - Google Patents
Compostos moduladores de fxr, seu uso e composição compreendendo os mesmosInfo
- Publication number
- BRPI0814571A2 BRPI0814571A2 BRPI0814571-7A2A BRPI0814571A BRPI0814571A2 BR PI0814571 A2 BRPI0814571 A2 BR PI0814571A2 BR PI0814571 A BRPI0814571 A BR PI0814571A BR PI0814571 A2 BRPI0814571 A2 BR PI0814571A2
- Authority
- BR
- Brazil
- Prior art keywords
- same
- modulating compounds
- composition understanding
- fxr modulating
- fxr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94997407P | 2007-07-16 | 2007-07-16 | |
PCT/US2008/069719 WO2009012125A1 (en) | 2007-07-16 | 2008-07-11 | Compounds and methods for modulating fxr |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0814571A2 true BRPI0814571A2 (pt) | 2015-01-06 |
Family
ID=39855171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0814571-7A2A BRPI0814571A2 (pt) | 2007-07-16 | 2008-07-11 | Compostos moduladores de fxr, seu uso e composição compreendendo os mesmos |
Country Status (31)
Country | Link |
---|---|
US (1) | US8153624B2 (pt) |
EP (1) | EP2178851B1 (pt) |
JP (1) | JP5373788B2 (pt) |
KR (1) | KR101157334B1 (pt) |
CN (1) | CN101743232B (pt) |
AR (1) | AR067540A1 (pt) |
AT (1) | ATE539065T1 (pt) |
AU (1) | AU2008276236B2 (pt) |
BR (1) | BRPI0814571A2 (pt) |
CA (1) | CA2693406C (pt) |
CL (1) | CL2008002051A1 (pt) |
CO (1) | CO6270212A2 (pt) |
CY (1) | CY1112298T1 (pt) |
DK (1) | DK2178851T3 (pt) |
DO (1) | DOP2010000018A (pt) |
EA (1) | EA016475B1 (pt) |
EC (1) | ECSP109879A (pt) |
ES (1) | ES2376176T3 (pt) |
HR (1) | HRP20120048T1 (pt) |
IL (1) | IL202234A0 (pt) |
MA (1) | MA31683B1 (pt) |
MX (1) | MX2010000502A (pt) |
PE (1) | PE20090809A1 (pt) |
PL (1) | PL2178851T3 (pt) |
PT (1) | PT2178851E (pt) |
RS (1) | RS52216B (pt) |
SI (1) | SI2178851T1 (pt) |
SV (1) | SV2010003458A (pt) |
TN (1) | TN2010000028A1 (pt) |
TW (1) | TW200906823A (pt) |
WO (1) | WO2009012125A1 (pt) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2289883A1 (en) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
EP2655369A1 (en) * | 2010-12-20 | 2013-10-30 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
WO2012087520A1 (en) * | 2010-12-20 | 2012-06-28 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
CA2905242C (en) | 2013-03-15 | 2016-11-29 | Pfizer Inc. | Indole compounds that activate ampk |
SI3043865T1 (sl) | 2013-09-11 | 2021-04-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Metode in farmacevtski sestavki za zdravljenje virusne okužbe s hepatitisom B |
ES2670984T3 (es) | 2013-11-05 | 2018-06-04 | Novartis Ag | Composiciones y métodos para modular receptores X farnesoides |
CN104045635A (zh) * | 2014-06-23 | 2014-09-17 | 华东理工大学 | 3,4,5-三取代异恶唑类化合物及其用途 |
EP3006939A1 (en) | 2014-10-06 | 2016-04-13 | Gilead Sciences, Inc. | Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation |
US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
EP3034501A1 (en) * | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxy containing FXR (NR1H4) modulating compounds |
EP3034499A1 (en) * | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
ES2905872T3 (es) | 2015-02-06 | 2022-04-12 | Intercept Pharmaceuticals Inc | Composiciones farmacéuticas para terapia combinada |
TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
SI3277286T1 (sl) | 2015-03-31 | 2021-09-30 | Enanta Pharmaceuticals, Inc. | Derivati žolčne kisline kot antagonisti FXR/TGR5 in metode za njihovo uporabo |
US10894054B2 (en) | 2015-04-07 | 2021-01-19 | Intercept Pharmaceuticals, Inc. | FXR agonist compositions for combination therapy |
CN106946867B (zh) * | 2016-01-06 | 2019-11-12 | 广州市恒诺康医药科技有限公司 | Fxr受体调节剂及其制备方法和用途 |
CN107021958A (zh) * | 2016-02-01 | 2017-08-08 | 山东轩竹医药科技有限公司 | Fxr受体激动剂 |
EP3437659B1 (en) | 2016-03-28 | 2023-03-01 | Intercept Pharmaceuticals, Inc. | Combination of a fxr agonist and an angiotensin ii receptor blocker |
US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
WO2017189663A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
WO2017189651A1 (en) * | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
US10144729B2 (en) | 2016-05-18 | 2018-12-04 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
US10138228B2 (en) | 2016-05-18 | 2018-11-27 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use therof |
US10149835B2 (en) | 2016-05-18 | 2018-12-11 | Elmore Patent Law Group, P.C. | Isoxazole derivatives as FXR agonists and methods of use thereof |
ES2921432T3 (es) | 2016-06-13 | 2022-08-25 | Gilead Sciences Inc | Derivados de azetidina como moduladores de FXR (NR1H4) |
CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
TW201808283A (zh) | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
US11091482B2 (en) | 2016-08-23 | 2021-08-17 | Ardelyx, Inc. | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators |
CN116854681A (zh) * | 2016-08-23 | 2023-10-10 | 阿德利克斯股份有限公司 | 用于治疗代谢病状和病症的激素受体调节剂 |
US11052069B2 (en) * | 2016-09-14 | 2021-07-06 | Novartis Ag | Regimes of FXR agonists |
US10450306B2 (en) * | 2016-10-04 | 2019-10-22 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
WO2018081285A1 (en) | 2016-10-26 | 2018-05-03 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof |
CN108017636A (zh) | 2016-11-04 | 2018-05-11 | 合帕吉恩治疗公司 | 作为fxr调节剂的含氮杂环化合物 |
CN108218852A (zh) * | 2016-12-15 | 2018-06-29 | 宁波百纳西药业有限公司 | 一种螺环化合物、其制备方法、组合物及用途 |
EP4424364A2 (en) | 2017-03-28 | 2024-09-04 | Gilead Sciences, Inc. | Methods of treating liver disease |
JP2020515564A (ja) | 2017-03-30 | 2020-05-28 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | エピソーマルウイルスの持続性及び発現を低下させるための方法及び医薬組成物 |
PT3612520T (pt) | 2017-04-12 | 2022-01-06 | Il Dong Pharma | Derivados de isoxazol como agonistas de recetores nucleares e utilizações dos mesmos |
CN109265471B (zh) * | 2017-06-30 | 2021-06-04 | 轩竹生物科技有限公司 | Fxr受体激动剂 |
CN109320509B (zh) * | 2017-07-31 | 2022-02-08 | 轩竹生物科技股份有限公司 | Fxr受体激动剂 |
EP3681881B1 (en) | 2017-09-14 | 2022-11-02 | Ardelyx, Inc. | Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders |
EP3704107B1 (en) | 2017-11-01 | 2023-04-12 | Bristol-Myers Squibb Company | Multicyclic compounds as farnesoid x receptor modulators |
PE20201184A1 (es) | 2017-11-01 | 2020-11-03 | Bristol Myers Squibb Co | Compuestos espirociclicos como moduladores del receptor farnesoide x |
JP7264906B2 (ja) * | 2017-11-01 | 2023-04-25 | ブリストル-マイヤーズ スクイブ カンパニー | ファルネソイドx受容体モジュレーターとしてのアルケン化合物 |
EA202091084A1 (ru) | 2017-11-01 | 2020-08-13 | Бристол-Маерс Сквибб Компани | Алкеновые спироциклические соединения как модуляторы фарнезоидных x-рецепторов |
WO2019089667A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Bridged bicyclic compounds as farnesoid x receptor modulators |
WO2019118571A1 (en) | 2017-12-12 | 2019-06-20 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
JP7243959B2 (ja) * | 2017-12-22 | 2023-03-22 | シチュアン ケルン-バイオテック バイオファーマシューティカル カンパニー リミテッド | イソオキサゾール誘導体、その製造方法、及びその使用 |
CN110128432B (zh) | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
WO2019160813A1 (en) | 2018-02-14 | 2019-08-22 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
CN110452235B (zh) * | 2018-05-08 | 2023-02-17 | 中国科学院上海药物研究所 | 一类含氟异噁唑类化合物及其制备方法、药物组合物和用途 |
KR20210052507A (ko) * | 2018-08-30 | 2021-05-10 | 테른스 파마슈티칼스, 인크. | 간 장애 치료 |
HUE065889T2 (hu) | 2019-01-15 | 2024-06-28 | Gilead Sciences Inc | Izoxazol vegyület mint FXR agonista és az azt tartalmazó gyógyszerészeti készítmények |
AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
US12030835B2 (en) | 2019-02-15 | 2024-07-09 | Bristol-Myers Squibb Company | Substituted amide compounds useful as farnesoid X receptor modulators |
EP3927683A1 (en) | 2019-02-19 | 2021-12-29 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
WO2020231917A1 (en) * | 2019-05-13 | 2020-11-19 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
EP3976049A1 (en) | 2019-05-30 | 2022-04-06 | Intercept Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease |
WO2021009332A1 (en) | 2019-07-18 | 2021-01-21 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
JP2023501386A (ja) * | 2019-11-08 | 2023-01-18 | ターンズ・ファーマシューティカルズ・インコーポレイテッド | 肝障害の治療 |
AU2021207253A1 (en) | 2020-01-15 | 2022-06-09 | Centre National De La Recherche Scientifique | Use of FXR agonists for treating an infection by hepatitis D virus |
US20210379043A1 (en) * | 2020-05-13 | 2021-12-09 | Terns Pharmaceuticals, Inc. | Combination treatment of liver disorders |
KR20230058112A (ko) | 2020-08-25 | 2023-05-02 | 일라이 릴리 앤드 캄파니 | Ssao 억제제의 다형체 |
IL301238A (en) * | 2020-09-11 | 2023-05-01 | Terns Pharmaceuticals Inc | Solid dispersible formulations of an FXR agonist |
KR20230088444A (ko) * | 2020-10-15 | 2023-06-19 | 일라이 릴리 앤드 캄파니 | fxr 작용제의 다형체 |
AU2022209084A1 (en) | 2021-01-14 | 2023-08-10 | Centre Leon Bérard | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
EP4329761A1 (en) | 2021-04-28 | 2024-03-06 | ENYO Pharma | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
CA3238082A1 (en) | 2021-11-11 | 2023-05-19 | Terns Pharmaceuticals, Inc. | Combination of a ssao inhibitor and thr-beta agonist for use in the treatment of liver disorders |
WO2023220404A1 (en) * | 2022-05-13 | 2023-11-16 | Terns Pharmaceuticals, Inc. | Treatment of non-alcoholic steatohepatitis |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07138258A (ja) * | 1993-11-16 | 1995-05-30 | Taiho Yakuhin Kogyo Kk | チアゾリジンジオン誘導体又はその塩 |
US6639078B1 (en) | 1998-12-23 | 2003-10-28 | Smithkline Beecham Corporation | Assays for ligands for nuclear receptors |
US6967212B2 (en) * | 2001-05-30 | 2005-11-22 | Bristol-Myers Squibb Company | Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method |
US7105556B2 (en) * | 2001-05-30 | 2006-09-12 | Bristol-Myers Squibb Company | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
DE60131967D1 (de) | 2001-08-13 | 2008-01-31 | Phenex Pharmaceuticals Ag | Nr1h4-kern-rezeptor-bindende verbindungen |
JP4541883B2 (ja) | 2002-07-09 | 2010-09-08 | ブリストル−マイヤーズ スクイブ カンパニー | 抗糖尿病薬および抗肥満症薬として有用な置換へテロ環誘導体、並びに方法 |
JP2006515838A (ja) * | 2002-11-22 | 2006-06-08 | スミスクライン ビーチャム コーポレーション | ファルネソイドx受容体アゴニスト |
US7863302B2 (en) * | 2006-02-03 | 2011-01-04 | Eli Lilly And Company | Compounds and methods for modulating FX-receptors |
EA015632B9 (ru) * | 2006-05-24 | 2012-08-30 | Эли Лилли Энд Компани | Агонисты fxr |
US8106077B2 (en) | 2006-05-24 | 2012-01-31 | Eli Lilly And Company | Compounds and methods for modulating FXR |
-
2008
- 2008-07-03 TW TW097125064A patent/TW200906823A/zh unknown
- 2008-07-11 PE PE2008001168A patent/PE20090809A1/es not_active Application Discontinuation
- 2008-07-11 CA CA2693406A patent/CA2693406C/en not_active Expired - Fee Related
- 2008-07-11 CN CN2008800247651A patent/CN101743232B/zh active Active
- 2008-07-11 AT AT08781651T patent/ATE539065T1/de active
- 2008-07-11 EA EA201070148A patent/EA016475B1/ru not_active IP Right Cessation
- 2008-07-11 PT PT08781651T patent/PT2178851E/pt unknown
- 2008-07-11 PL PL08781651T patent/PL2178851T3/pl unknown
- 2008-07-11 WO PCT/US2008/069719 patent/WO2009012125A1/en active Application Filing
- 2008-07-11 EP EP08781651A patent/EP2178851B1/en active Active
- 2008-07-11 AU AU2008276236A patent/AU2008276236B2/en not_active Ceased
- 2008-07-11 JP JP2010517082A patent/JP5373788B2/ja active Active
- 2008-07-11 BR BRPI0814571-7A2A patent/BRPI0814571A2/pt not_active IP Right Cessation
- 2008-07-11 SI SI200830514T patent/SI2178851T1/sl unknown
- 2008-07-11 US US12/600,879 patent/US8153624B2/en active Active
- 2008-07-11 RS RS20120099A patent/RS52216B/en unknown
- 2008-07-11 DK DK08781651.8T patent/DK2178851T3/da active
- 2008-07-11 MX MX2010000502A patent/MX2010000502A/es active IP Right Grant
- 2008-07-11 KR KR1020107000896A patent/KR101157334B1/ko not_active IP Right Cessation
- 2008-07-11 ES ES08781651T patent/ES2376176T3/es active Active
- 2008-07-14 AR ARP080103026A patent/AR067540A1/es not_active Application Discontinuation
- 2008-07-14 CL CL2008002051A patent/CL2008002051A1/es unknown
-
2009
- 2009-11-19 IL IL202234A patent/IL202234A0/en unknown
-
2010
- 2010-01-12 CO CO10002335A patent/CO6270212A2/es not_active Application Discontinuation
- 2010-01-12 DO DO2010000018A patent/DOP2010000018A/es unknown
- 2010-01-15 TN TNP2010000028A patent/TN2010000028A1/fr unknown
- 2010-01-15 SV SV2010003458A patent/SV2010003458A/es not_active Application Discontinuation
- 2010-01-15 EC EC2010009879A patent/ECSP109879A/es unknown
- 2010-02-11 MA MA32615A patent/MA31683B1/fr unknown
-
2012
- 2012-01-16 HR HR20120048T patent/HRP20120048T1/hr unknown
- 2012-01-27 CY CY20121100098T patent/CY1112298T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0814571A2 (pt) | Compostos moduladores de fxr, seu uso e composição compreendendo os mesmos | |
NL301192I2 (nl) | Finerenon en zijn zouten, solvaten en solvaten van de zouten daarvan | |
BRPI0912356A2 (pt) | compostos moduladores de sirtuína, composição farmacêutica compreendendo os mesmos e seu uso | |
BRPI0811635A2 (pt) | Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos | |
BRPI0821027A2 (pt) | 4-(4-ciano-2-tioaril) dihidropirimidinonas e seu uso | |
BRPI0814593A2 (pt) | Composto, composição farmacêutica que o contém e uso do composto. | |
BRPI0821276A2 (pt) | Produto, e, uso do produto | |
BRPI0821668A2 (pt) | Uso | |
BRPI0618904A2 (pt) | composto, composição farmacêutica, e, uso do composto | |
BRPI0813770A2 (pt) | Composição, e, uso de uma composição | |
BRPI0813627A2 (pt) | Peptídio antimicrobiano, composições e métodos de uso | |
BR112012004335A2 (pt) | composto, composição farmacêutica, e, uso do composto. | |
BRPI0815709A2 (pt) | composro, composição farmacêutica, e, uso de um composto. | |
BRPI0907453A2 (pt) | Compostos, uso e preparação dos mesmos | |
BRPI0614205A2 (pt) | composto, composição farmacêutica, e, uso de composto | |
BRPI0819299A2 (pt) | Uso de composição, e, composição contendo proteína | |
BRPI0923500A2 (pt) | uso e composição farmacêutica compreendendo agonista ou modulador do receptor s1p, e kit. | |
BRPI0822104A2 (pt) | Composições antimicrobianas e métodos para o uso das mesmas | |
BRPI0808013A2 (pt) | Compostos de quinoxalina e uso dos mesmos | |
BRPI0808172A2 (pt) | Compostos heterocíclicos, composições compreendendo-os e métodos de seu uso. | |
BRPI0814420A2 (pt) | composição, e, uso de álcool alcoxilado. | |
BRPI0907365A2 (pt) | Composição antimicrobiana e uso | |
BRPI0718192A2 (pt) | Corantes dispersos, sua preparação e seu uso. | |
BRPI0813587A2 (pt) | Composto, uso do mesmo, e, composição farmacêutica | |
BRPI0906444A2 (pt) | Compostos de 4-piridinona e seu uso para câncer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |